{
  "id": "d0124273bd68ebfb",
  "title": "Why Subcutaneous Darzalex Faspro Matters for Patients With Multiple Myeloma",
  "description": "20260211T041500Z",
  "content": "",
  "source": "curetoday.com",
  "source_url": "https://www.curetoday.com/view/why-subcutaneous-darzalex-faspro-matters-for-patients-with-multiple-myeloma",
  "published_at": "20260211T041500Z",
  "fetched_at": "2026-02-12T00:28:38.246764+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.curetoday.com/view/why-subcutaneous-darzalex-faspro-matters-for-patients-with-multiple-myeloma",
    "url_mobile": "",
    "title": "Why Subcutaneous Darzalex Faspro Matters for Patients With Multiple Myeloma",
    "seendate": "20260211T041500Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/curetoday/e177162a14c3a04673f1a8adb0ea32bce6bc9555-1280x720.jpg",
    "domain": "curetoday.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}